Aquestive Therapeutics, Inc. Finite-Lived Intangible Assets, Accumulated Amortization
Aquestive Therapeutics, Inc. (AQST) had Finite-Lived Intangible Assets, Accumulated Amortization of $4.37 million as of 2025-12-31, per its 10-K filed 2026-03-04.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization · last filed 2026-03-04
- 2025-12-31: Finite-Lived Intangible Assets, Accumulated Amortization $4.37M.
- 2025-09-30: Finite-Lived Intangible Assets, Accumulated Amortization $4.37M.
- 2025-06-30: Finite-Lived Intangible Assets, Accumulated Amortization $4.37M.
- 2025-03-31: Finite-Lived Intangible Assets, Accumulated Amortization $4.37M.
| Period end | Finite-Lived Intangible Assets, Accumulated Amortization |
|---|---|
| 2025-12-31 | $4.37M 10-K · filed 2026-03-04 |
| 2025-09-30 | $4.37M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $4.37M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $4.37M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $4.37M 10-K · filed 2026-03-04 |
| 2024-09-30 | $4.37M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $4.37M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $3.13M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $3.09M 10-K · filed 2025-03-05 |
| 2023-09-30 | $3.05M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $3.01M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $2.97M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $2.93M 10-K · filed 2024-03-05 |
| 2022-09-30 | $2.88M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $2.84M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $2.83M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $2.82M 10-K · filed 2023-03-31 |
| 2021-09-30 | $2.80M 10-Q · filed 2021-11-02 |
| 2021-06-30 | $2.79M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $2.78M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $2.77M 10-K · filed 2022-03-08 |
| 2020-09-30 | $2.75M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $2.74M 10-Q · filed 2020-08-04 |
| 2020-03-31 | $2.73M 10-Q · filed 2020-05-05 |
| 2019-12-31 | $2.71M 10-K · filed 2021-03-09 |
| 2019-09-30 | $2.70M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $2.69M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $2.68M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $2.66M 10-K · filed 2020-03-11 |
| 2017-12-31 | $2.61M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |